Abstract: This review on indicated prevention adds to the current knowledge and understanding of risk factors in the development of later drug problems and dependence, focusing on the mental health and behavioural problems that develop during childhood. Indicated prevention is a relatively new branch of drug prevention and can be seen as the third part of the ’prevention chain’, after universal and selective prevention. Its aim is not necessarily to prevent drug use or initiation to it, but rather to prevent the development of dependence, diminish frequency of use and avert ’dangerous’ patterns of substance use (e.g. moderate instead of binge-drinking).

Abstract: This report presents the results and outlines the key achievements for 2010 on the information exchange, risk-assessment and control of new psychoactive substances. In 2010, 41 new psychoactive substances were officially notified for the first time in the European Union through the Early-Warning System (EWS). Of those, 15 were synthetic cathinones and 11 were synthetic cannabinoids. Substances belonging to more established chemical families were also reported – five phenethylamines, one tryptamine and one piperazine. The list of newly notified substances was rather diverse and also included a plant-based substance, a synthetic cocaine, a ketamine derivative, a phencyclidine derivative, an indane, a benzofuran, as well as a substance which can be seen as a designer medicine. The report also describes the increased availability of ’legal highs’ and the EMCDDA’s activities in monitoring the online shops selling these products, as well as the risk assessment of mephedrone, which was submitted to control measures and criminal penalties throughout the European Union.

Abstract: The main purpose of the European School Survey Project on alcohol and Other Drugs (ESPAD) is to collect comparable data on substance use among 15- to 16-year-old European students in order to monitor trends within as well as between countries. So far, five data-collection waves have been conducted in the framework of the project. The first study was carried out in 26 countries in 1995, while data collection in 2011 was performed in 37 countries. However, results for 2011 are available only for 36 countries, since the Isle of Man collected data but unfortunately did not have the possibility to deliver any results. This summary presents key results from the 2011 survey in the ESPAD countries as well as findings regarding the long-term trends. An initial section gives a short overview of the methodology. Independent research teams in the participating countries form the basis of the collaborative project. In the 2011 ESPAD data collection, more than 100 000 students took part in the following countries: Albania, Belgium (Flanders), Bosnia and Herzegovina (Republic of Srpska), Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, the Faroe Islands, Finland, France, Germany (five Bundesländer), Greece, Hungary, Iceland, Ireland, the Isle of Man, Italy, Latvia, Liechtenstein, Lithuania, Malta, Moldova, Monaco, Montenegro, Norway, Poland, Portugal, Romania, the Russian Federation (Moscow), Serbia, Slovakia, Slovenia, Sweden, Ukraine and the United Kingdom. Spain, like the United States, is not an ESPAD country. However, as a result of close collaboration with the ESPAD project since 1995, data from the Spanish National Students Drug Survey have been included when comparable/feasible, and are available throughout the 2011 ESPAD Report.